Alexandra Scheeler | Senior Regulatory Affairs Associate
Openbiome

Appearances:

Microbiome World Congress USA Day 2 2017 @ 09:20

Plenary Panel: Regulations in response to the Microbiome

• How do you work with regulators in development of Microbiome treatments?
• How do you prevent Wild West scenarios where many companies are promoting their product and operating without oversight?
• From FMT, Prebiotics to Probiotics, from food supplements to traditional treatments- what protocols must be established for such a wide variety of products?
• What standards are necessary and what does solid translational evidence look like in judging the efficacy of microbial treatments?

Matthew Henn, SVP, Head of Drug Discovery & Bioinformatics, Seres Therapeutics

×

Matthew Henn / Plenary Panel: Regulations in response to the Microbiome

Matthew Henn, SVP, Head of Drug Discovery & Bioinformatics,
Seres Therapeutics

Matthew Henn Senior VP, Head of Drug Discovery and Bioinformatics, Seres Therapeutics Matthew Henn is the Senior Vice President and Head of Drug Discovery & Bioinformatics of Seres. He has more than 16 years of combined research experience in microbial ecology, genomics, and bioinformatics...

CloseMore

Kathleen Basmadjian, Senior Director, Global Regulatory Policy & Intelligence, Global Regulatory Affairs, Janssen

×

Kathleen Basmadjian / Plenary Panel: Regulations in response to the Microbiome

Kathleen Basmadjian, Senior Director, Global Regulatory Policy & Intelligence, Global Regulatory Affairs,
Janssen

Kathleen Basmadjian, PhDJanssen Research & Development, LLC.  Kathleen concentrates on coalescing cross-sector and global regulatory policy as a Senior Director in the Janssen R&D Global Regulatory Policy and Intelligence team within the pharmaceutical sector of Johnson & Johnson. ...

CloseMore

Alexandra Scheeler, Senior Regulatory Affairs Associate, Openbiome